Los Angeles Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$466K Sell
48,900
-306,155
-86% -$2.38M ﹤0.01% 893
2025
Q4
$2.57M Buy
355,055
+45,945
+15% +$332K 0.01% 399
2025
Q3
$2.35M Buy
309,110
+210,064
+212% +$1.75M 0.01% 463
2025
Q2
$887K Sell
99,046
-2,332
-2% -$21.7K ﹤0.01% 678
2025
Q1
$760K Buy
101,378
+190
+0.2% +$1.53K ﹤0.01% 641
2024
Q4
$761K Buy
101,188
+14,655
+17% +$111K ﹤0.01% 705
2024
Q3
$658K Sell
86,533
-11,044
-11% -$84K ﹤0.01% 785
2024
Q2
$603K Buy
97,577
+7,963
+9% +$43.9K ﹤0.01% 806
2024
Q1
$455K Buy
89,614
+36,284
+68% +$204K ﹤0.01% 903
2023
Q4
$319K Buy
53,330
+20,202
+61% +$117K ﹤0.01% 1000
2023
Q3
$235K Buy
33,128
+506
+2% +$3.64K ﹤0.01% 1031
2023
Q2
$230K Buy
+32,622
New +$262K ﹤0.01% 1086
2022
Q4
Sell
-14,285
Closed -$180K 1192
2022
Q3
$180K Buy
+14,285
New +$184K ﹤0.01% 1180
2021
Q2
Sell
-30,950
Closed -$315K 1540
2021
Q1
$315K Sell
30,950
-147,375
-83% -$1.52M ﹤0.01% 1417
2020
Q4
$1.33M Buy
178,325
+48,855
+38% +$252K 0.01% 812
2020
Q3
$445K Buy
129,470
+46,515
+56% +$199K ﹤0.01% 1128
2020
Q2
$395K Sell
82,955
-36,225
-30% -$145K ﹤0.01% 1197
2020
Q1
$238K Buy
119,180
+30,130
+34% +$83K ﹤0.01% 1130
2019
Q4
$307K Buy
+89,050
New +$224K ﹤0.01% 1124
2017
Q4
Sell
-25,170
Closed -$132K 1318
2017
Q3
$132K Buy
+25,170
New +$129K ﹤0.01% 1276
2015
Q2
Sell
-12,860
Closed -$116K 1206
2015
Q1
$116K Buy
+12,860
New +$133K ﹤0.01% 1187

Other funds holding BCRX